FDA allow patients w/ life threatening disease to begin using new therapies before formal FDA approval Under this, patients may receive investigational drugs that have shown promise in Phase II clinical trials. Patients are INFORMED THAT THEY ACCEPT SOME RISK in using drug products NOT YET APPROVED but seriously ill patients are typically willing to accept more risk.